Charles S. Venuto

1.6k total citations
40 papers, 759 citations indexed

About

Charles S. Venuto is a scholar working on Infectious Diseases, Neurology and Virology. According to data from OpenAlex, Charles S. Venuto has authored 40 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 10 papers in Neurology and 10 papers in Virology. Recurrent topics in Charles S. Venuto's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (10 papers) and Parkinson's Disease Mechanisms and Treatments (9 papers). Charles S. Venuto is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (10 papers) and Parkinson's Disease Mechanisms and Treatments (9 papers). Charles S. Venuto collaborates with scholars based in United States, United Kingdom and Switzerland. Charles S. Venuto's co-authors include Karl Kieburtz, E. Ray Dorsey, Qing Ma, Gene D. Morse, Vinayak Venkataraman, Andrew McGarry, Tanya Simuni, Andrew H. Talal, David Oakes and Diane Wuest and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Charles S. Venuto

39 papers receiving 743 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles S. Venuto United States 16 280 177 145 128 97 40 759
Suman Kushwaha India 19 166 0.6× 88 0.5× 238 1.6× 92 0.7× 117 1.2× 84 1.0k
Anne McDonnell United States 12 156 0.6× 171 1.0× 236 1.6× 64 0.5× 83 0.9× 23 766
Lorena Cuenca‐Bermejo Spain 12 102 0.4× 52 0.3× 112 0.8× 251 2.0× 93 1.0× 27 587
Bo Jin China 19 76 0.3× 165 0.9× 157 1.1× 45 0.4× 201 2.1× 70 1.2k
Danfeng Yu China 9 259 0.9× 89 0.5× 105 0.7× 51 0.4× 103 1.1× 19 638
Mildred D. Gottwald United States 16 178 0.6× 336 1.9× 254 1.8× 65 0.5× 620 6.4× 25 1.7k
S. Aubrey Stoch United States 12 26 0.1× 90 0.5× 102 0.7× 59 0.5× 35 0.4× 26 383
Rohan Sharma United States 13 248 0.9× 75 0.4× 108 0.7× 108 0.8× 72 0.7× 61 710
Elodie L. Plan Sweden 15 62 0.2× 37 0.2× 85 0.6× 55 0.4× 61 0.6× 36 752
R. A. A. Maes Netherlands 17 30 0.1× 94 0.5× 177 1.2× 41 0.3× 37 0.4× 32 788

Countries citing papers authored by Charles S. Venuto

Since Specialization
Citations

This map shows the geographic impact of Charles S. Venuto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles S. Venuto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles S. Venuto more than expected).

Fields of papers citing papers by Charles S. Venuto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles S. Venuto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles S. Venuto. The network helps show where Charles S. Venuto may publish in the future.

Co-authorship network of co-authors of Charles S. Venuto

This figure shows the co-authorship network connecting the top 25 collaborators of Charles S. Venuto. A scholar is included among the top collaborators of Charles S. Venuto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles S. Venuto. Charles S. Venuto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schneider, Ruth B., et al.. (2025). Constructing a Personalized Treatment Rule for Initial Therapy in Early Parkinson's Disease. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 46(1). e70069–e70069.
2.
Bernal, Edgar A., et al.. (2024). Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease. Clinical and Translational Science. 17(11). e70066–e70066. 4 indexed citations
3.
Venuto, Charles S., et al.. (2023). Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design. Movement Disorders. 38(10). 1774–1785. 3 indexed citations
4.
Kieburtz, Karl, et al.. (2022). Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease. Movement Disorders Clinical Practice. 9(7). 961–966. 4 indexed citations
5.
Surmeier, D. James, Jack Nguyen, Nicola Lancki, et al.. (2021). Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease. Movement Disorders. 37(2). 334–342. 29 indexed citations
6.
Talal, Andrew H., Charles S. Venuto, Gene D. Morse, et al.. (2020). Toward precision prescribing for methadone: Determinants of methadone deposition. PLoS ONE. 15(4). e0231467–e0231467. 14 indexed citations
7.
Ma, Qing, Giovanni Schifitto, Charles S. Venuto, et al.. (2020). Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB). Journal of Neuroimmune Pharmacology. 15(1). 7–9. 6 indexed citations
8.
Wang, Pengyi, Charles S. Venuto, Raymond Cha, & Benjamin L. Miller. (2020). Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV. Analytical Methods. 12(14). 1882–1888. 2 indexed citations
9.
Latourelle, Jeanne C., Michael T. Beste, Tiffany C. Hadzi, et al.. (2017). Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. The Lancet Neurology. 16(11). 908–916. 106 indexed citations
10.
Gupta, Samir K., Douglas Kitch, Todd T. Brown, et al.. (2017). Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. PMC. 1 indexed citations
11.
Venuto, Charles S., Jihoon Lim, Susan Messing, et al.. (2017). Inflammation Investigated as a Source of Pharmacokinetic Variability of Atazanavir in AIDS Clinical Trials Group Protocol A5224s. Antiviral Therapy. 23(4). 345–351. 7 indexed citations
12.
Venuto, Charles S., et al.. (2017). Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct‐Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications. Clinical Pharmacology in Drug Development. 6(2). 135–139. 4 indexed citations
13.
Verma, Anurag, Yuki Bradford, Shefali S. Verma, et al.. (2017). Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and Genomics. 27(3). 101–111. 8 indexed citations
14.
Venuto, Charles S., Qing Ma, Eric S. Daar, et al.. (2017). Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Therapeutic Drug Monitoring. 39(6). 596–603. 10 indexed citations
15.
Luque, Amneris E., Barry S. Zingman, Margaret A. Fischl, et al.. (2016). Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. Current Vascular Pharmacology. 14(3). 280–287. 8 indexed citations
16.
Wanga, Valentine, Charles S. Venuto, Gene D. Morse, et al.. (2015). Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and Genomics. 25(9). 450–461. 17 indexed citations
17.
Johnson, Daniel, Charles S. Venuto, Marylyn D. Ritchie, et al.. (2014). Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and Genomics. 24(4). 195–203. 34 indexed citations
18.
Ma, Qing, Barry S. Zingman, Amneris E. Luque, et al.. (2011). Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals With Active Substance-Related Disorders. Therapeutic Drug Monitoring. 33(3). 309–314. 3 indexed citations
19.
Venuto, Charles S., Andrew McGarry, Qing Ma, & Karl Kieburtz. (2011). Pharmacologic approaches to the treatment of Huntington's disease. Movement Disorders. 27(1). 31–41. 64 indexed citations
20.
Venuto, Charles S., Mary Butler, Elizabeth Dodds Ashley, & Jack Brown. (2010). Alternative Therapies for Clostridium difficile Infections. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(12). 1266–1278. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suman Kushwaha Breakdown of academic impact, for papers by Anne McDonnell Breakdown of academic impact, for papers by Lorena Cuenca‐Bermejo Breakdown of academic impact, for papers by Bo Jin Breakdown of academic impact, for papers by Danfeng Yu Breakdown of academic impact, for papers by Mildred D. Gottwald Breakdown of academic impact, for papers by S. Aubrey Stoch Breakdown of academic impact, for papers by Rohan Sharma Breakdown of academic impact, for papers by Elodie L. Plan Breakdown of academic impact, for papers by R. A. A. Maes
Rankless by CCL
2026